FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166607747> ?p ?o ?g. }

• W3166607747 endingPage "4101" @default.
• W3166607747 startingPage "4101" @default.
• W3166607747 abstract "4101 Background: Anti–PD-(L)1 plus anti-CTLA-4 therapies (e.g. nivolumab/ipilimumab, tremelimumab/durvalumab) produce durable immune responses in patients (pts) with advanced hepatocellular carcinoma (HCC). More recent data suggests that the combination of immune checkpoint inhibitors (ICIs) with a multi-kinase inhibitor is efficacious against unresectable HCC (uHCC). AK104 is a humanized IgG1 bispecific antibody that simultaneously binds to PD-1 and CTLA-4. Early data suggests that AK104 possesses encouraging anti-tumor activity in selected tumour types and an improved safety profile compared to the co-administration of anti-PD-1 plus anti-CTLA-4 antibodies. Lenvatinib is a multi-kinase inhibitor and approved for first-line treatment of uHCC. Here, we report results from a phase 2 study of AK104 plus lenvatinib in pts with uHCC. Methods: In this single-arm, multicenter phase II study (NCT04444167), pts with uHCC, BCLC stage B or C, Child-Pugh class A, who had not previously received systemic treatment received AK104 (6 mg/kg IV q2w or 15 mg/kg IV q3w) and lenvatinib (8 mg [bodyweight < 60 kg] or 12 mg [weight ≥ 60 kg] PO QD). Primary endpoint was objective response rate (ORR) per RECIST v1.1. Secondary endpoints include disease control rate (DCR), duration of response (DOR), progression-free survival (PFS) and overall survival (OS). Results: As of February 1 2021, 30 pts (86.7% male, median age 52.5yrs [31-71], 30% was ECOG 1, 93.3% was HBV+) had received the combination therapy of (AK104 6 mg/kg q2w plus lenvatinib). Of 18 pts evaluable for antitumor activity (defined as pts with the opportunity to be followed for at least 2 scans [≥13 weeks]), ORR per RECIST v1.1 was 44.4% (8/18), DCR was 77.8% (8 PRs and 6 SDs including 2 pts who had 28.4% and 29.2% reduction in tumor size from baseline). Median PFS has not been reached. Treatment-related adverse events (TRAEs) occurred in 83.3% of pts (G3 TRAEs occurred in 26.7% [8/30], and no G4 TRAEs or TRAEs leading to death). Most common TRAEs (≥15%) were increased AST (36.7%) and ALT (36.7%), decreased platelet count (33.3%), decreased neutrophil count (30.0%), and increased blood bilirubin (26.7%), with the vast majority being grades 1 or 2. Conclusions: AK104 plus lenvatinib as first-line therapy for uHCC has showed promising antitumor activity and an acceptable safety profile. Toxicities were manageable, with no unexpected safety signals. Enrollment for AK104 15 mg/kg q3w plus lenvatinib is currently ongoing, and longer follow-up is needed to further evaluate the durability of response. Clinical trial information: NCT04444167." @default.
• W3166607747 created "2021-06-22" @default.
• W3166607747 creator A5001325524 @default.
• W3166607747 creator A5004641991 @default.
• W3166607747 creator A5008691080 @default.
• W3166607747 creator A5008923395 @default.
• W3166607747 creator A5014295844 @default.
• W3166607747 creator A5029143856 @default.
• W3166607747 creator A5029600413 @default.
• W3166607747 creator A5032001090 @default.
• W3166607747 creator A5046525642 @default.
• W3166607747 creator A5074582238 @default.
• W3166607747 creator A5087661837 @default.
• W3166607747 creator A5090872533 @default.
• W3166607747 date "2021-05-20" @default.
• W3166607747 modified "2023-09-30" @default.
• W3166607747 title "Phase 2 study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma." @default.
• W3166607747 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.4101" @default.
• W3166607747 hasPublicationYear "2021" @default.
• W3166607747 type Work @default.
• W3166607747 sameAs 3166607747 @default.
• W3166607747 citedByCount "20" @default.
• W3166607747 countsByYear W31666077472021 @default.
• W3166607747 countsByYear W31666077472022 @default.
• W3166607747 countsByYear W31666077472023 @default.
• W3166607747 crossrefType "journal-article" @default.
• W3166607747 hasAuthorship W3166607747A5001325524 @default.
• W3166607747 hasAuthorship W3166607747A5004641991 @default.
• W3166607747 hasAuthorship W3166607747A5008691080 @default.
• W3166607747 hasAuthorship W3166607747A5008923395 @default.
• W3166607747 hasAuthorship W3166607747A5014295844 @default.
• W3166607747 hasAuthorship W3166607747A5029143856 @default.
• W3166607747 hasAuthorship W3166607747A5029600413 @default.
• W3166607747 hasAuthorship W3166607747A5032001090 @default.
• W3166607747 hasAuthorship W3166607747A5046525642 @default.
• W3166607747 hasAuthorship W3166607747A5074582238 @default.
• W3166607747 hasAuthorship W3166607747A5087661837 @default.
• W3166607747 hasAuthorship W3166607747A5090872533 @default.
• W3166607747 hasConcept C121608353 @default.
• W3166607747 hasConcept C126322002 @default.
• W3166607747 hasConcept C143998085 @default.
• W3166607747 hasConcept C159654299 @default.
• W3166607747 hasConcept C203014093 @default.
• W3166607747 hasConcept C203092338 @default.
• W3166607747 hasConcept C2776264508 @default.
• W3166607747 hasConcept C2776694085 @default.
• W3166607747 hasConcept C2777701055 @default.
• W3166607747 hasConcept C2777742743 @default.
• W3166607747 hasConcept C2778019345 @default.
• W3166607747 hasConcept C2778650287 @default.
• W3166607747 hasConcept C2778695046 @default.
• W3166607747 hasConcept C2780030458 @default.
• W3166607747 hasConcept C2781433595 @default.
• W3166607747 hasConcept C31760486 @default.
• W3166607747 hasConcept C535046627 @default.
• W3166607747 hasConcept C71924100 @default.
• W3166607747 hasConcept C90924648 @default.
• W3166607747 hasConceptScore W3166607747C121608353 @default.
• W3166607747 hasConceptScore W3166607747C126322002 @default.
• W3166607747 hasConceptScore W3166607747C143998085 @default.
• W3166607747 hasConceptScore W3166607747C159654299 @default.
• W3166607747 hasConceptScore W3166607747C203014093 @default.
• W3166607747 hasConceptScore W3166607747C203092338 @default.
• W3166607747 hasConceptScore W3166607747C2776264508 @default.
• W3166607747 hasConceptScore W3166607747C2776694085 @default.
• W3166607747 hasConceptScore W3166607747C2777701055 @default.
• W3166607747 hasConceptScore W3166607747C2777742743 @default.
• W3166607747 hasConceptScore W3166607747C2778019345 @default.
• W3166607747 hasConceptScore W3166607747C2778650287 @default.
• W3166607747 hasConceptScore W3166607747C2778695046 @default.
• W3166607747 hasConceptScore W3166607747C2780030458 @default.
• W3166607747 hasConceptScore W3166607747C2781433595 @default.
• W3166607747 hasConceptScore W3166607747C31760486 @default.
• W3166607747 hasConceptScore W3166607747C535046627 @default.
• W3166607747 hasConceptScore W3166607747C71924100 @default.
• W3166607747 hasConceptScore W3166607747C90924648 @default.
• W3166607747 hasIssue "15_suppl" @default.
• W3166607747 hasLocation W31666077471 @default.
• W3166607747 hasOpenAccess W3166607747 @default.
• W3166607747 hasPrimaryLocation W31666077471 @default.
• W3166607747 hasRelatedWork W2285109017 @default.
• W3166607747 hasRelatedWork W2800311363 @default.
• W3166607747 hasRelatedWork W3000961096 @default.
• W3166607747 hasRelatedWork W3036371943 @default.
• W3166607747 hasRelatedWork W3104083510 @default.
• W3166607747 hasRelatedWork W3119432592 @default.
• W3166607747 hasRelatedWork W3166607747 @default.
• W3166607747 hasRelatedWork W3170189973 @default.
• W3166607747 hasRelatedWork W3186656946 @default.
• W3166607747 hasRelatedWork W4284973751 @default.
• W3166607747 hasVolume "39" @default.
• W3166607747 isParatext "false" @default.
• W3166607747 isRetracted "false" @default.
• W3166607747 magId "3166607747" @default.
• W3166607747 workType "article" @default.